Stay updated on Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page.

Latest updates to the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page
- Check2 days agoChange DetectedThe page's revision label updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision: v3.4.3 replaces v3.4.2. This appears to be a minor version update with no visible changes to study content.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check38 days agoChange DetectedFallopian tube cancer was added to the conditions list and Genetic and Rare Diseases Information Center resources were added. The page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check45 days agoChange DetectedRevision tag updated from v3.4.0 to v3.4.1. No visible changes to the study details were observed.SummaryDifference0.0%

- Check52 days agoChange DetectedAdded a 'Show glossary' option and the 'No FEAR Act Data' text. Updated footer labels to 'Last Update Submitted that Met QC Criteria' and introduced 'Revision: v3.4.0'.SummaryDifference0.2%

- Check67 days agoChange DetectedThe page revision label was updated from v3.3.3 to v3.3.4; there are no substantive changes to study details, eligibility criteria, or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Niraparib & Pembrolizumab in TNBC & Ovarian Cancer Clinical Trial page.